Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer

Genet, S.; Visser, Esther; Borne, Ben E. E. M. van den; Soud, Maggy Youssef-El; Belderbos, Huub; Stege, Gerben; Saegher, Marleen E A de; Eduati, Federica; Broeren, Maarten A. C.; Dongen, Joost van; Brunsveld, Luc; Kerkhof, Daan van de; Scharnhorst, Volkher

doi:10.18632/oncotarget.27664

Cited by 10 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood NSE is currently considered as a reliable tumor marker of SCLC as far as diagnosis, prognosis, and follow up is concerned [85,86]. Increased NSE is also reported in NSCLC [87,88].…”

Section: Discussionmentioning

confidence: 99%

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Dutta¹

2021

J Neurosci Neurol Disord

View full text Add to dashboard Cite

Parkinson’s disease (PD) is thought to be the most common neurodegenerative disease with movement disorder. The key motor symptoms are rigidity, tremor, akinesis/hypokinesia/bradykinesia, and postural instability. However, in our day-to-day clinical practice we tend to see several other symptoms which may be motor or non-motor. Non-motor symptoms (NMS) are quite common and debilitating. The pathological hallmarks of PD are loss of dopaminergic neurons in the substantia nigra pars compacta (SNPc) and accumulation of unfolded or misfolded alpha-synuclein. Diagnosis of PD is difficult in the pre-motor stage. Late diagnosis renders a substantial loss of dopaminergic neurons in SNPc and spread of disease in other parts of the brain. This may manifest as either full blown symptoms requiring multiple medications or may even lead to life threatening condition due to lack of early diagnostic tools and techniques. Biomarkers are required to diagnose PD at a very early stage when prevention is possible. Hence, we see a lot of interest among researchers involved in finding a biomarker specific to the disease. Biomarkers may be clinical, image based, genetic, and biochemical. Cerebrospinal fluid (CSF) and serum markers which may correlate with disease pathophysiology are of great significance. One such molecule which recently gained a lot of attention is neuron-specific enolase (NSE). The main aim of this paper is to highlight the role of NSE in predicting neurodegeneration and neuroinflammation ultimately reflecting damage of brain cells in PD.

show abstract

“…Blood NSE is currently considered as a reliable tumor marker of SCLC as far as diagnosis, prognosis, and follow up is concerned [85,86]. Increased NSE is also reported in NSCLC [87,88].…”

Section: Discussionmentioning

confidence: 99%

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Dutta¹

2021

J Neurosci Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Clinical samples of lung cancer patients were pooled and used for assay comparison. The samples were selected from a clinical study (lung marker study NL9146, ICTRP Search Portal (who.int)) described elsewhere [16,[23][24][25], ethically approved by the Medical Research Ethics Committees United (NL58985.100.16).…”

Section: Study Design and Participantsmentioning

confidence: 99%

“…Improved diagnostic value was observed by combining NSE detection with the assessment of other protein tumor markers such as cytokeratin fragment 21-1 [8][9][10][11][12]. Nevertheless, the clinical applicability of NSE quantification using the traditional sandwich immunoassays is hampered by the lack of concordance between assays and the falsely elevated concentrations caused by hemolysis [13][14][15][16]. Above all, the inability to separately quantify the αγ and γγ dimers limits the opportunity to investigate their individual added value in lung cancer diagnostics.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Neuron‑Specific Enolase Isozymes in Human Serum Using Immunoaffinity Purification and Liquid Chromatography‑Tandem Mass Spectrometry Quantification

Genet

Wolfs

et al. 2023

Preprint

View full text Add to dashboard Cite

“…Among them, CEA was first reported in gastrointestinal carcinoma in 1965 and it has since been found to be upregulated in colorectal and lung cancer [ 3 ]. CYFRA21-1 and NSE were expressed in lung cancer and could be biomarkers of small cell lung cancer [ 4 , 5 ]. Carcinoma diagnosis needs histopathological confirmation.…”

Section: Introductionmentioning

confidence: 99%

“…CEA, NSE, CYFRA21-1, and Hsp90α were tumor markers, which can be used as diagnostic tools. However, in order to improve the diagnostic efficiency, multiple tumor markers are usually detected and analyzed at the same time [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

The diagnostic value of Hsp90? in monitoring treatment responses in lung cancer

Wang¹,

JIANG²,

LIU³

2022

Turkish Journal of Medical Sciences

View full text Add to dashboard Cite

Background/aim Heat shock protein 90α (Hsp90α) is considered a tumor biomarker in many human malignancies. This study investigated the diagnostic value of Hsp90α combined with other traditional lung cancer biomarkers (CEA, CYFRA21-1, and NSE) and its role in monitoring the treatment response of lung cancer patients. Materials and methods A total of 205 patients with lung cancer and 186 patients with lung benign disease who were admitted to our hospital were enrolled from 2018 to 2020. The 205 patients included 76 cases of squamous, 92 cases of adenocarcinoma, and 37 cases of small cell lung cancer. There were 49 patients with TNM I+II and 156 patients with TNM III+IV. A total of 10 mL baseline peripheral venous blood samples and subsequent peripheral venous blood samples (7 days after two cycles of chemotherapy) were collected, and the levels of Hsp90α, carcinoembryonic antigen (CEA), Cytokeratin 19 fragments (CYFRA21-1), and neuron-specific enolase (NSE) were detected by ELISA kit. Results Hsp90α was obviously higher in serum from patients with lung cancer than in patients with benign lung disease (p < 0.0001). Moreover, Hsp90α levels were higher in patients with advanced-stage (stage III–IV) lung cancer compared to those with early-stage (stage I–II). Hsp90α level was significantly decreased following treatment with chemotherapy in the progress partial response group (p = 0.017), whereas the level of Hsp90α was significantly higher after chemotherapy treatment in the progressive disease group (p < 0.0001). In addition, compared with CYFRA21-1, CEA, or NSE alone, the AUC of Hsp90α combined with CYFRA21-1, CEA, or NSE were significantly higher in the diagnosis of adenocarcinoma or small-cell lung cancer. Conclusion Hsp90α combined with CYFRA21-1, CEA, and NSE can be used as diagnostic indicators of lung cancer. The Hsp90α level can be used to monitor treatment response.

show abstract

Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer

Cited by 10 publications

References 26 publications

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Analysis of Neuron‑Specific Enolase Isozymes in Human Serum Using Immunoaffinity Purification and Liquid Chromatography‑Tandem Mass Spectrometry Quantification

The diagnostic value of Hsp90? in monitoring treatment responses in lung cancer

Contact Info

Product

Resources

About